Antipodes Partners’s Entrada Therapeutics TRDA Stock Holding History

Antipodes Partners’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$14.8K	Buy	+2,333	New	+$16.2K	﹤0.01%	143

Other funds holding TRDA

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Antipodes Partners's TRDA Position: Q3 2026 in Review

Antipodes Partners opened a new position in Entrada Therapeutics (TRDA) in Q3 2026: 2,333 shares worth $14.8K. The stake represents ﹤0.01% of the portfolio and ranks #143 among its holdings.

76 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

Antipodes Partners held 2,333 shares of Entrada Therapeutics worth $14.8K as of Q3 2026.
Entrada Therapeutics was a new Antipodes Partners position in Q3 2026.
Entrada Therapeutics made up ﹤0.01% of Antipodes Partners's portfolio in Q3 2026, its #143 holding.
76 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on Antipodes Partners's 13F filing for Q3 2026, filed 5 Nov 2026.